Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07719530 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Aug 1, 2026 to Aug 4, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Aug 1, 2026 to Aug 4, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a randomized, double-blind, multi-center, parallel, phase II clinical trial, aiming to evaluate the efficacy and safety of SHR-1139 injection for adult patients with psoriasis. The trial includes a 4-week screening period, a 52-week treatment period, and a 12-week safety follow-up period. Approximately 60 patients with psoriasis are expected to participate.
Trial Details
NCT Number NCT07719530
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Psoriasis
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov